Md Mahmudul Hassan,
Poster Author Of 2 e-Posters
EFFECT OF PCV-10 ON INVASIVE PNEUMOCOCCAL DISEASE AMONG BANGLADESHI CHILDREN
IMPACT OF 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-10) ON PNEUMONIA HOSPITALIZATION RATE AMONG BANGLADESHI CHILDREN
Author Of 2 Presentations
IMPACT OF 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-10) ON PNEUMONIA HOSPITALIZATION RATE AMONG BANGLADESHI CHILDREN (ID 1134)
Abstract
Background
Bangladesh introduced PCV-10 in March 2015 with a 3+0 schedule. We assessed impact of PCV-10 on pneumonia and severe pneumonia among children <5 years.
Methods
Children <5 years were enrolled following WHO’s Invasive Bacterial Vaccine Preventable Disease surveillance criteria. January 2011 to March 2015 was considered as baseline and April 2015 to June 2019 as post-PCV era. PCV-10 impact was measured based on hospitalization rate (adjusted with all hospitalized patients) of pneumonia and severe pneumonia using (I) WHO case definitions and (II) physician’s diagnosis.
Results
Analysis using WHO’s case definition didn’t show any significant changes in pneumonia admissions among those <5 years or 3-23 months. Similarly, no impact was noted for admissions of physician-diagnosed pneumonia. However, physician-diagnosed severe pneumonia episodes decreased 82% (95% CI: 78.9%-84.2%) from 4.5%-0.8% among those <5 years and 76.1% (95% CI 69.8%-81.2%) from 4.4 -1% among children 3-23 months.
Conclusions
The lack of significant change for WHO-defined pneumonia and severe pneumonia or physician-diagnosed pneumonia may be due to a lack of specificity in the definitions, including many illnesses not caused by pneumococcal infection. Reduction in severe pneumonia admissions (among which more cases are expected to be bacterial), suggests a role of PCV-10 in reduction of pneumococcal pneumonia.
EFFECT OF PCV-10 ON INVASIVE PNEUMOCOCCAL DISEASE AMONG BANGLADESHI CHILDREN (ID 1010)
Abstract
Background
Bangladesh introduced PCV-10 in March 2015 using a 3+0 schedule. We evaluated PCV-10 effect on invasive pneumococcal disease (IPD) among children <5 years.
Methods
IPD surveillance is ongoing in four sentinel hospitals. Numbers of children with pneumococcus detected from a sterile site (IPD cases) were adjusted using number of febrile children tested with blood and/ CSF each year as the denominator. Data from pre-vaccine baseline (January 2012 to March 2015) and post-vaccine (April 2015 to September 2019) periods were compared to determine PCV-10 impact by age group. Serotypes in PCV-10 plus 6A were considered vaccine types (VT).
Results
We identified 543 children with IPD among 60,921 children tested during 2012 to September 2019. IPD rates among children <5 years decreased 61% (CI: 45.8-72.4%) between baseline (137/10,000 tested) and 2019 (53/10,000; Figure-A); VT IPD rates fell 71% (CI: 47.2-85.4%; 53 to 15/10,000). Among children 3-23 months, IPD declined 70% (CI: 54.9-81.9%) between baseline (207/10,000) and 2019 (63/10,000; Figure-B); VT rates dropped 87% [(CI: 65.2-96.5%); 81 to 10/10,000]. Nonvaccine-serotype IPD rates were stable.
Conclusions
PCV-10 introduction resulted in large reductions of overall and VT IPD among young children. In contrast to reports from elsewhere, serotype replacement is not yet evident in Bangladesh.